Introduction
Major depressive disorder (MDD) has a lifetime prevalence of 11-15% (Bromet et al., 2011) and is the leading cause of disability worldwide (World Health Organization, 2017) . It is a clinically heterogeneous disease of variable course in which the core symptoms, low mood and loss of interest, are related to emotional dysregulation. Recent research has demonstrated that also cognitive impairments play an important role in the symptomatology of MDD (Rock et al., 2014; Trivedi and Greer, 2014) . These include reversible dysfunctions that largely normalize after a major depressive episode, that is, visuospatial short term memory function (Behnken et al., 2010) , and persistent cognitive impairments remaining after remission, such as attention and executive functions (Rock et al., 2014; Årdal and Hammar, 2011) . In a meta-analysis investigating executive function in 375 depressed patients and 481 control subjects, patients were found to perform significantly worse in tasks measuring semantic verbal fluency, cognitive flexibility and impulse inhibition (Wagner et al., 2012) . Clinically significant impairments in several cognitive domains including psychomotor speed, attention, visual learning and memory, and executive functions have repeatedly been shown to be associated with MDD (Gallagher et al., 2007; Marazziti et al., 2010; Trivedi and Greer, 2014) .
As the biological underpinning of MDD is largely unknown, so are the biological mechanisms mediating the cognitive deficits in MDD. Of the various hypotheses for MDD, the monoamine deficiency hypothesis is the most investigated (Agurell, 1981; Coppen, 1967) . The monoaminergic hypothesis is mainly based on observations of clinical effects of antidepressant drugs. The currently most widely used pharmacological treatment for MDD is selective serotonin reuptake inhibitors (SSRIs), which inhibit the serotonin transporter and modify serotonin concentration in the synaptic cleft (Lundberg et al., 2007; Nord et al., 2013; Romero et al., 1996) . Additional support for an association between serotonin and depression comes from tryptophan depletion studies showing that acute tryptophan depletion results in increased depressive symptoms in remitted MDD patients and subjects with a family history of MDD (Ruhé et al., 2007) .
To date, 14 different receptor subtypes for serotonin have been identified in the mammalian brain. With molecular positron emission tomography (PET), specific receptor and transporter proteins can be quantified in the living human brain. In a majority of PET studies of the serotonin system in patients with MDD, differences in 5-HT 1A receptor as well as serotonin transporter binding compared to control subjects have been found (Gryglewski et al., 2014; Savitz and Drevets, 2013) . The serotonin receptor 1B (5-HT1BR) has only recently been investigated in MDD. As a heteroreceptor it regulates the release of neurotransmitters such as dopamine or GABA. As an autoreceptor it is involved in the negative feedback mechanism that controls the release of serotonin (Celada et al., 2013; Ruf and Bhagwagar, 2009) . Preclinical studies indicate a role of the 5-HT1BR in various behavioral functions such as locomotor activity and aggression (Ramboz et al., 1996) , sleep (Boutrel et al., 1999) , learning (Wolff et al., 2003) and learned helplessness (McDevitt et al., 2011) .
Human in vivo studies of the 5-HT1BR have been scarce, but with PET and the 5-HT1BR radioligand [
11 C]AZ10419369 correlations have been shown between [ 11 C]AZ10419369 binding in grey matter and creativity fluency both in control subjects and in patients with Parkinson Disease (Varrone et al., 2015) . In a study of aggression, a positive correlation was found between trait anger and serotonin 1B receptor binding in striatum (da Cunha-Bang et al., 2016) . Also, differences in 5-HT1BR binding have been reported after psychotherapy in depressed patients (Tiger et al., 2014) as well as in comparison to a control group (Murrough et al., 2011; Tiger et al., 2016) . Taken together, recent research in both animals and humans suggest a role for 5-HT1BR in several aspects of cognitive function and personality, and in the pathophysiology of MDD. Nevertheless, the relation between cognitive changes in MDD and 5-HT1BR binding still remains to be characterized. The limited success of research on the biological underpinning of MDD has raised questions concerning the definition of biologically relevant phenotypes. Cognitive functions affected in mood disorder has been suggested as examples of intermediate phenotypes more robustly related to biological markers (Hasler et al., 2004) . This study was thus designed to explore cognitive domains impaired in MDD
